Clinical Trial Update: Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stem Cells [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating allogeneic mesenchymal stem cells for treatment of severe COVID-19 pneumonia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• Allogeneic mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: Red de Terapia Celular | Conditions: COVID-19 Pneumonia | Phase 2 | Status: COMPLETED